Evogene logo

EVGN - Evogene Share Price

$3.89 0.8  25.9%

Last Trade - 25/09/20

Consumer Defensives
Small Cap
Market Cap £78.6m
Enterprise Value £59.6m
Revenue £460k
Position in Universe 4293rd / 6417
Unlock EVGN Revenue
Relative Strength (%)
1m +148.5%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.51%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
14.5 11.1 6.54 3.38 1.75 0.75 195.7 190.1 -44.7%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Evogene Ltd revenues decreased 31% to $373K. Net loss applicable to common stockholders increased 34% to $10.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Development Costs increase of 21% to $8.5M (expense), Financing income decrease of 66% to $643K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


EVGN Revenue Unlock EVGN Revenue

Net Income

EVGN Net Income Unlock EVGN Revenue

Normalised EPS

EVGN Normalised EPS Unlock EVGN Revenue

PE Ratio Range

EVGN PE Ratio Range Unlock EVGN Revenue

Dividend Yield Range

EVGN Dividend Yield Range Unlock EVGN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
EVGN EPS Forecasts Unlock EVGN Revenue
Profile Summary

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd. (Evofuel). It operates through two segments. Its Evogene segment develops seed traits, ag-chemical products, and ag-biological products to improve plant performance. The Company's Evofuel segment develops species of the castor bean plant for second generation feedstock for biofuel and other industrial uses. Its Crop Enhancement (CE) division is developing two types of products: CE seed traits, are seed traits having improved yield and abiotic stress tolerance, and ag-biologicals, which focuses on microbial-based bio-stimulants. The Company's Crop Protection (CP) division is developing two types of products: CP seed traits and ag-chemicals.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated October 10, 1999
Public Since June 11, 2007
No. of Shareholders: n/a
No. of Employees: 150
Sector Consumer Defensives
Industry Food & Tobacco
Index Nasdaq Composite ,
Exchange NASDAQ Global Market (Dual Listing)
Shares in Issue 25,754,297
Free Float (0.0%)
Eligible for
EVGN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for EVGN
Upcoming Events for EVGN
Frequently Asked Questions for Evogene
What is the Evogene share price?

As of 25/09/20, shares in Evogene are trading at $3.89, giving the company a market capitalisation of £78.6m. This share price information is delayed by 15 minutes.

How has the Evogene share price performed this year?

Shares in Evogene are currently trading at $3.89 and the price has moved by 0.131k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Evogene price has moved by 0.111k% over the past year.

What are the analyst and broker recommendations for Evogene?

Of the analysts with advisory recommendations for Evogene, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Evogene is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Evogene next release its financial results?

Evogene is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Evogene dividend yield?

Evogene does not currently pay a dividend.

Does Evogene pay a dividend?

Evogene does not currently pay a dividend.

When does Evogene next pay dividends?

Evogene does not currently pay a dividend.

How do I buy Evogene shares?

To buy shares in Evogene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Evogene?

Shares in Evogene are currently trading at $3.89, giving the company a market capitalisation of £78.6m.

Where are Evogene shares listed? Where are Evogene shares listed?

Here are the trading details for Evogene:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: EVGN
What kind of share is Evogene?

Based on an overall assessment of its quality, value and momentum, Evogene is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Evogene share price forecast 2020?

We were not able to load any forecast data for Evogene.

How can I tell whether the Evogene share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evogene. Over the past six months, the relative strength of its shares against the market has been 0.197k%. At the current price of $3.89, shares in Evogene are trading at 0.182k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Evogene PE Ratio?

We were not able to find PE ratio data for Evogene.

Who are the key directors of Evogene?

Evogene's management team is headed by:

Martin Gerstel - CHM
Ofer Haviv - PRE
Hagai Karchi - CTO
Sarit Firon - IND
Alex Taskar - CFO
Kinneret Livnat Savitsky - IND
Oded Shoseyov - DRC
Ido Dor - EVP
Arnon Heyman - VPR
Mark Kapel - EVP
Eran Kosover - EVP
Alin Sela-Brown - VPR
Ziv Kop - IND
Adrian Percy - DRC
Who are the major shareholders of Evogene?

Here are the top five shareholders of Evogene based on the size of their shareholding:

Ivy Investment Management Company Investment Advisor
Percentage owned: 10.71% (2.76m shares)
Ivy Science and Technology Fund Mutual Fund
Percentage owned: 10.17% (2.62m shares)
Migdal Investment Portfolio Management (1998) Ltd Investment Advisor
Percentage owned: 7.37% (1.90m shares)
Alpha Capital Aktiengesellschaft Holding Company
Percentage owned: 6.85% (1.76m shares)
Phoenix Investment and Finances Ltd Investment Advisor
Percentage owned: 6.84% (1.76m shares)
Similar to EVGN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.